Mealey's (May 16, 2019, 1:07 PM EDT) -- WASHINGTON, D.C. — A New Jersey federal judge’s finding that two patents covering the pain-reliever drug “Vimovo” are adequately described under Section 112 of the Patent Act, 35 U.S.C. § 112, was reversed May 15 by the Federal Circuit U.S. Court of Appeals (Nuvo Pharmaceuticals v. Dr. Reddy’s Laboratories Inc., et al., No. 17-2473, Fed. Cir., 2019 U.S. App. LEXIS 14345)....